Centaurus Financial’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Centaurus Financial’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$177K	Buy	4,051 +26	+0.6%	+$1.2K	0.01%	859
2025 Q4	$183K	Sell	4,025 -202	-5%	-$8.95K	0.01%	836
2025 Q3	$164K	Buy	4,227 +490	+13%	+$17.7K	0.01%	863
2025 Q2	$126K	Sell	3,737 -237	-6%	-$7.5K	0.01%	875
2025 Q1	$126K	Buy	3,974 +25	+0.6%	+$949	0.01%	819
2024 Q4	$153K	Buy	3,949 +200	+5%	+$8.4K	0.01%	748
2024 Q3	$169K	Buy	3,749 +246	+7%	+$11K	0.01%	680
2024 Q2	$146K	Buy	+3,503	New	+$146K	0.01%	684
2024 Q1	–	Sell	-3,185	Closed	-$147K	–	800
2023 Q4	$147K	Buy	3,185 +406	+15%	+$16.6K	0.01%	660
2023 Q3	$113K	Buy	2,779 +118	+4%	+$5.37K	0.01%	695
2023 Q2	$129K	Buy	2,661 +22	+0.8%	+$1.1K	0.01%	675
2023 Q1	$130K	Buy	2,639 +489	+23%	+$25.2K	0.01%	776
2022 Q4	$109K	Buy	+2,150	New	+$111K	0.01%	766
2022 Q2	–	Sell	-1,749	Closed	-$105K	–	862
2022 Q1	$105K	Buy	1,749 +31	+2%	+$1.96K	0.01%	855
2021 Q4	$136K	Buy	1,718 +436	+34%	+$36.6K	0.01%	794
2021 Q3	$114K	Buy	+1,282	New	+$120K	0.01%	825

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

USCWA

U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Centaurus Financial's GNOM Position: Q1 2026 in Review

Centaurus Financial increased its Global X Genomics & Biotechnology ETF (GNOM) stake by 0.65% in Q1 2026, buying an estimated $1.2K and bringing the position to 4,051 shares worth $177K. The position accounts for 0.01% of the portfolio, ranked #859.

Centaurus Financial first reported a position in GNOM in Q3 2021 and has held it in 16 quarters since. The position peaked at $183K in Q4 2025. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

Centaurus Financial held 4,051 shares of Global X Genomics & Biotechnology ETF worth $177K as of Q1 2026.
Centaurus Financial bought 26 Global X Genomics & Biotechnology ETF shares in Q1 2026, an estimated $1.2K.
Global X Genomics & Biotechnology ETF made up 0.01% of Centaurus Financial's portfolio in Q1 2026, its #859 holding.
Centaurus Financial first reported a position in Global X Genomics & Biotechnology ETF in Q3 2021 and has held it in 16 quarters since.
Centaurus Financial's Global X Genomics & Biotechnology ETF position peaked at $183K in Q4 2025.
40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.